163 related articles for article (PubMed ID: 31155916)
1. Dalbavancin Use in the Emergency Department Setting.
Patel M; Smalley S; Dubrovskaya Y; Siegfried J; Caspers C; Pham V; Press RA; Papadopoulos J
Ann Pharmacother; 2019 Nov; 53(11):1093-1101. PubMed ID: 31155916
[No Abstract] [Full Text] [Related]
2. Use of a telehealth follow-up system to facilitate treatment and discharge of emergency department patients with severe cellulitis.
Koziatek C; Klein N; Mohan S; Lakdawala V; Swartz J; Femia R; Press R; Caspers C
Am J Emerg Med; 2021 Mar; 41():184-189. PubMed ID: 32081554
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
4. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.
Keyloun KR; Lofgren E; Hebert S
J Med Econ; 2019 Jul; 22(7):652-661. PubMed ID: 30838908
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
7. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
8. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
[TBL] [Abstract][Full Text] [Related]
9. Real world utilization of Dalbavancin at a rural community emergency department.
Dolan A; Kuge E; Bremmer E; Dietrich T; Santarelli A; Ashurst J
Am J Emerg Med; 2022 Apr; 54():253-256. PubMed ID: 35190304
[TBL] [Abstract][Full Text] [Related]
10. Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections.
Donnelly D; Pillinger KE; Debnath A; DePasquale W; Munsiff S; Louie T; Jones CMC; Shulder S
Am J Health Syst Pharm; 2024 May; 81(Supplement_2):S40-S48. PubMed ID: 38465838
[TBL] [Abstract][Full Text] [Related]
11. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
[TBL] [Abstract][Full Text] [Related]
12. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
[TBL] [Abstract][Full Text] [Related]
13. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Gonzalez J; Andrade DC; Niu J
Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
[TBL] [Abstract][Full Text] [Related]
14. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
Roecker AM; Pope SD
Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
[TBL] [Abstract][Full Text] [Related]
17. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
[TBL] [Abstract][Full Text] [Related]
19. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]